Jump to main content
Jump to site search


Recent development of lipoxygenase inhibitors as anti-inflammatory agents

Author affiliations

Abstract

Inflammation is favorable in most cases, because it is a kind of body defensive response to external stimuli; sometimes, inflammation is also harmful, such as attacks on the body's own tissues. It could be that inflammation is a unified process of injury and resistance to injury. Inflammation brings extreme pain to patients, showing symptoms of rubor, swelling, fever, pain and dysfunction. As the specific mechanism is not clear yet, the current anti-inflammatory agents are given priority for relieving suffering of patients. Thus it is emergent to find new anti-inflammatory agents with rapid effect. Lipoxygenase (LOX) is a kind of rate-limiting enzyme in the process of arachidonic acid metabolism into leukotriene (LT) which mediates the occurrence of inflammation. The inhibition of LOX can reduce LT, thereby producing an anti-inflammatory effect. In this review, the LOX inhibitors reported in recent years are summarized, and, in particular, their activities, structure–activity relationships and molecular docking studies are emphasized, which will provide new ideas to design novel LOX inhibitors.

Graphical abstract: Recent development of lipoxygenase inhibitors as anti-inflammatory agents

Back to tab navigation

Publication details

The article was received on 31 Jul 2017, accepted on 28 Nov 2017 and first published on 29 Nov 2017


Article type: Review Article
DOI: 10.1039/C7MD00390K
Citation: Med. Chem. Commun., 2018, Advance Article
  •   Request permissions

    Recent development of lipoxygenase inhibitors as anti-inflammatory agents

    C. Hu and S. Ma, Med. Chem. Commun., 2018, Advance Article , DOI: 10.1039/C7MD00390K

Search articles by author

Spotlight

Advertisements